Other Clinical Trial - Diabetic Ketoacidosis From New SGLT2i: Can Genomics

Status Recruiting

Clinical Trial Summary

Sodium glucose co-transporter 2 (SGLT2) inhibitors have revolutionized care for people living with type 2 diabetes mellitus (T2DM). They reduce a person's risk of heart failure, renal failure, myocardial infarction, stroke, cardiovascular mortality, and potentially all-cause mortality. Remarkably, some of these benefits also extend to people who do not have T2DM. While the benefits of SGLT2 inhibitors are impressive, there is one life-threatening side effect associated with their use: diabetic ketoacidosis (DKA). The ability to predict which patients are at highest risk of DKA is needed to sufficiently mitigate this risk. Moreover, considering the impressive benefits of SGLT2 inhibitors, identifying patients at the lowest risk of SGLT2 inhibitor-associated DKA is also important so that providers do not overestimate risk in those who stand to benefit most. Advances in genomic technologies and related analyses have provided unprecedented opportunities to bring genomics-driven precision medicine initiatives to the forefront of clinical research. Leading these developments has been the progress made by genome-wide association studies (GWAS) due to decreasing genotyping costs, and consequently, the ability to routinely study large numbers of patients. These approaches allow for systematic screening of the genome in an unbiased manner and have accelerated the discovery of genetic variants and novel biological processes that contribute to the development of adverse treatment outcomes. By using innovative approaches, which harness large cohorts of population controls, sample size limitations that are associated with rare adverse drug reactions such as SGLT2 inhibitor-associated DKA can be overcome. The DANGER study represents a highly innovative new direction wherein partnership among basic science researchers and computational biologists will lead to the application of genomic techniques to identify genetic variants that may be associated with SGLT2 inhibitor-associated DKA.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05402579
Study type	Observational
Source	Mount Sinai Hospital, Canada
Contact	Michael Fralick, MD, PhD
Phone	4165864800
Email	mike.fralick@sinaihealth.ca
Status	Recruiting
Phase
Start date	July 29, 2022
Completion date	June 6, 2024

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT05530356` - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Active, not recruiting	`NCT04954313` - Baseline Oral Health Study: UnCoVer the Connections to General Health	Phase 4
Completed	`NCT01354925` - Management of Type-2 Diabetic Patients Treated With Insulin During the Ramadan	Phase 4
Completed	`NCT01206725` - Exercise Study on Cardiac Function in Patients With Diabetes Mellitus Type 2 and Diastolic Dysfunction	N/A
Completed	`NCT00997282` - A Study of OPC-262 in Patients With Type 2 Diabetes	Phase 2/Phase 3
Completed	`NCT00637546` - Gait and Balance of Diabetes Type 2 Patients	Phase 2/Phase 3
Completed	`NCT00464880` - Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic Nephropathy	Phase 1/Phase 2
Withdrawn	`NCT02057497` - An Exploratory Clinical Trial to Generate Whole Blood Samples for Analysing Genetic Polymorphisms	N/A
Active, not recruiting	`NCT05014204` - Safety and Feasibility of Novel Therapy for Duodenal Mucosal Regeneration for Type II Diabetes	N/A
Recruiting	`NCT03662217` - Personalized Nutrition for Diabetes Type 2	N/A
Completed	`NCT04276051` - Cryovagotomy Diabetes Trial	N/A
Completed	`NCT02569684` - Effects of Prebiotics on GLP-1 in Type 2 Diabetes	N/A
Active, not recruiting	`NCT01933529` - ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)	Phase 2
Terminated	`NCT01722474` - Assessment of Three Instruments for the Non-invasive Measurement of Arterial Stiffness.	N/A
Completed	`NCT00977262` - Postprandial Inflammation and Fatty Acids	N/A
Completed	`NCT00518427` - Evaluate Quality of Life in Type 2 Diabetes, Before and After Change to Insuline Glargine	Phase 4
Recruiting	`NCT05378620` - Project Dulce for Filipino-Americans With Type 2 Diabetes	N/A
Recruiting	`NCT03834207` - A Study of the Usefulness & Usability of a Healthcare IT System for Managing Multi-morbidity and Poly-pharmacy	N/A
Active, not recruiting	`NCT05228067` - Enhancing Brain Health by tDCS in Persons With Overweight and Obesity	N/A
Active, not recruiting	`NCT05689684` - Arabinoxylan-oligosaccharides (AXOS) for the Management of Type-2 Diabetes	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Diabetic Ketoacidosis From New SGLT2i: Can Genomics Estimate Risk — DaNGER

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms